Stephen Broderick

Bloomberg (United States) — United States

Medicine · Health Sciences

38h-index12.5kcitations183works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Diagnosis and Treatment(73), Lung Cancer Treatments and Mutations(64), Cancer Immunotherapy and Biomarkers(53), Esophageal Cancer Research and Treatment(35), Gastric Cancer Management and Outcomes(25)

Publications181 total

Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025Open Access
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025Open Access
National Analysis of Anastomotic Leak and Subsequent Failure to Rescue After Esophagectomy
Journal of Surgical Research·2025
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
Journal of Clinical Oncology·2025· 8 cited
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
New England Journal of Medicine·2025· 77 cited
Longitudinal tumor-informed cfDNA whole genome sequencing to capture residual disease during neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer.
Journal of Clinical Oncology·2025
Figure S3 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Figure S2 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Figure S6 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Figure S1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Figure S5 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Figure S4 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Supplementary Tables 1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Data from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2025Open Access
Thoracic Surgery Outcomes Research Network (ThORN) Consensus Document on Defining a High-Quality Wedge Resection for Early-Stage Lung Cancer
The Annals of Thoracic Surgery·2025· 5 cited
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Journal of Clinical Oncology·2025· 23 citedOpen Access
Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i> Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Clinical Cancer Research·2024· 9 citedOpen Access
Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy
Cancers·2024· 8 citedOpen Access
1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
Annals of Oncology·2024· 1 cited
The Society of Thoracic Surgeons 2024 Risk Models for Lung Cancer Resection: Continued Refinement and Improved Outcomes
The Annals of Thoracic Surgery·2024· 3 cited
page 1 of 10Next →

Frequent Co-authors

Varun Puri(23), Traves D. Crabtree(19), G. Alexander Patterson(18), Daniel Kreisel(15), Bryan F. Meyers(15), Alexander S. Krupnick(14), Valerie W. Rusch(11), Patrick M. Forde(10), Julie R. Brahmer(10), Clifford G. Robinson(9), Aalok Patel(8), Jennifer M. Bell(8), William Pao(7), Stephen C. Yang(7), David R. Jones(7), Pamela Samson(7), Marc Ladanyi(6), Richard J. Battafarano(6), Drew M. Pardoll(6), Jamie E. Chaft(5)